Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Significant Increase in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 31st total of 1,520,000 shares. Currently, 5.2% of the shares of the company are short sold. Based on an average trading volume of 773,000 shares, the short-interest ratio is presently 2.2 days.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently modified their holdings of the company. American Century Companies Inc. raised its position in Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after purchasing an additional 12,656 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Werewolf Therapeutics by 43.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 160,577 shares of the company’s stock valued at $392,000 after buying an additional 48,952 shares during the last quarter. Renaissance Technologies LLC boosted its position in Werewolf Therapeutics by 103.1% during the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after buying an additional 86,800 shares during the period. Marshall Wace LLP grew its holdings in Werewolf Therapeutics by 410.5% during the 2nd quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after acquiring an additional 107,900 shares during the last quarter. Finally, Millennium Management LLC increased its position in Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after acquiring an additional 544,881 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on HOWL shares. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th. JMP Securities decreased their target price on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a report on Tuesday, January 14th.

Werewolf Therapeutics Price Performance

Shares of HOWL stock traded up $0.03 on Monday, reaching $1.37. The company had a trading volume of 412,510 shares, compared to its average volume of 283,414. The business’s 50-day moving average is $1.58 and its 200 day moving average is $2.01. The stock has a market capitalization of $61.05 million, a PE ratio of -0.90 and a beta of 0.36. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a one year low of $1.26 and a one year high of $8.19.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.